Glycomimetics

Glycomimetics company information, Employees & Contact Information

Explore related pages

Related company profiles:

At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with cancers and inflammatory diseases such as acute myeloid leukemia and sickle cell disease. Our mission is to improve outcomes for patients by advancing our research and clinical candidates, providing hope for patients as we strive to deliver breakthrough treatments. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies. Our leading researchers leverage their deep understanding of the role that carbohydrates play in cell recognition processes and use our proprietary chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation. We harness our development and commercial expertise to move our wholly-owned drug candidates from research through late-stage clinical development. We are a public company traded on the NASDAQ under the symbol GLYC.

Company Details

Employees
16
Founded
-
Address
9708 Medical Center Drive, Rockville,md 20850,united States
Phone
2402431207
Email
we****@****ics.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Rockville, MD
Looking for a particular Glycomimetics employee's phone or email?

Glycomimetics Questions

News

GlycoMimetics Stockholders Approve Merger with Crescent Biopharma and All Related Proposals - citybiz

GlycoMimetics Stockholders Approve Merger with Crescent Biopharma and All Related Proposals citybiz

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma - Business Wire

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma Business Wire

Harout Semerjian: I am incredibly proud to have worked alongside such passionate individuals - Oncodaily

Harout Semerjian: I am incredibly proud to have worked alongside such passionate individuals Oncodaily

Glycomimetics down and out on upro miss | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Glycomimetics down and out on upro miss | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

GlycoMimetics fails phase 3 blood cancer trial, causing investors to sour on stock - Fierce Biotech

GlycoMimetics fails phase 3 blood cancer trial, causing investors to sour on stock Fierce Biotech

Diversity-oriented synthesis of glycomimetics - Communications Chemistry - Nature

Diversity-oriented synthesis of glycomimetics - Communications Chemistry Nature

Sialyl Lewisx Glycomimetics as E- and P-Selectin Antagonists Targeting Hyperinflammation - ACS Publications

Sialyl Lewisx Glycomimetics as E- and P-Selectin Antagonists Targeting Hyperinflammation ACS Publications

GlycoMimetics Announces Merger with Crescent Biopharma - Yahoo Finance

GlycoMimetics Announces Merger with Crescent Biopharma Yahoo Finance

GlycoMimetics Inc. (GLYC) reports earnings - qz.com

GlycoMimetics Inc. (GLYC) reports earnings qz.com

Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia - ScienceDirect.com

Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia ScienceDirect.com

GlycoMimetics adjusts merger terms with Crescent Biopharma - Investing.com

GlycoMimetics adjusts merger terms with Crescent Biopharma Investing.com

Targeting Galectins With Glycomimetics - Frontiers

Targeting Galectins With Glycomimetics Frontiers

Massive $200M Biotech Deal: Crescent Biopharma Secures Funding for Cancer Breakthrough Pipeline - Stock Titan

Massive $200M Biotech Deal: Crescent Biopharma Secures Funding for Cancer Breakthrough Pipeline Stock Titan

Crescent Biopharma Completes Closing of Merger with - GlobeNewswire

Crescent Biopharma Completes Closing of Merger with GlobeNewswire

GlycoMimetics gets on the PD-1/VEGF bandwagon | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

GlycoMimetics gets on the PD-1/VEGF bandwagon | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer - citybiz

GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer citybiz

Crescent inks GlycoMimetics merger, securing Nasdaq listing and $200M for hot cancer program - Fierce Biotech

Crescent inks GlycoMimetics merger, securing Nasdaq listing and $200M for hot cancer program Fierce Biotech

GlycoMimetics and Crescent Biopharma Announce Merger Plans - Yahoo Finance

GlycoMimetics and Crescent Biopharma Announce Merger Plans Yahoo Finance

GlycoMimetics Amends Merger Agreement With Crescent Biopharma - Investing.com

GlycoMimetics Amends Merger Agreement With Crescent Biopharma Investing.com

GlycoMimetics Names Harout Semerjian as CEO - citybiz

GlycoMimetics Names Harout Semerjian as CEO citybiz

Vaccination with Tumor-Ganglioside Glycomimetics Activates a Selective Immunity that Affords Cancer Therapy - ScienceDirect.com

Vaccination with Tumor-Ganglioside Glycomimetics Activates a Selective Immunity that Affords Cancer Therapy ScienceDirect.com

Glycomimetics could prevent COVID-19 from infecting human cells - Drug Target Review

Glycomimetics could prevent COVID-19 from infecting human cells Drug Target Review

A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis - ScienceDirect.com

A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis ScienceDirect.com

GlycoMimetics Stockholders Approve Merger with Crescent Biopharma - TipRanks

GlycoMimetics Stockholders Approve Merger with Crescent Biopharma TipRanks

Crescent Biopharma Completes Merger with GlycoMimetics - TipRanks

Crescent Biopharma Completes Merger with GlycoMimetics TipRanks

GLYCOMIMETICS INC SEC 10-Q Report - TradingView

GLYCOMIMETICS INC SEC 10-Q Report TradingView

Diabetic endothelial colony forming cells have the potential for restoration with glycomimetics - Nature

Diabetic endothelial colony forming cells have the potential for restoration with glycomimetics Nature

Glycomimetics wilts on missed acute myeloid leukemia phase III - BioWorld MedTech

Glycomimetics wilts on missed acute myeloid leukemia phase III BioWorld MedTech

GlycoMimetics shares nearly cut in half as Pfizer-partnered phase 3 drug flops - Fierce Biotech

GlycoMimetics shares nearly cut in half as Pfizer-partnered phase 3 drug flops Fierce Biotech

AML Drug Candidate Granted Breakthrough Therapy Designation - Medical Professionals Reference

AML Drug Candidate Granted Breakthrough Therapy Designation Medical Professionals Reference

Pfizer, GlycoMimetics Phase III Drug Fails Phase III Trial for Sickle Cell Complication - Genetic Engineering and Biotechnology News

Pfizer, GlycoMimetics Phase III Drug Fails Phase III Trial for Sickle Cell Complication Genetic Engineering and Biotechnology News

GlycoMimetics Inc (GLYC) Q4 2020 Earnings Call Transcript - The Motley Fool

GlycoMimetics Inc (GLYC) Q4 2020 Earnings Call Transcript The Motley Fool

Gem -diamine 1- N -iminosugars as versatile glycomimetics: synthesis, biological activity and therapeutic potential - Nature

Gem -diamine 1- N -iminosugars as versatile glycomimetics: synthesis, biological activity and therapeutic potential Nature

Top Glycomimetics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant